CA2245497A1 - Peptide immunogens for vaccination against and treatment of allergy - Google Patents

Peptide immunogens for vaccination against and treatment of allergy

Info

Publication number
CA2245497A1
CA2245497A1 CA002245497A CA2245497A CA2245497A1 CA 2245497 A1 CA2245497 A1 CA 2245497A1 CA 002245497 A CA002245497 A CA 002245497A CA 2245497 A CA2245497 A CA 2245497A CA 2245497 A1 CA2245497 A1 CA 2245497A1
Authority
CA
Canada
Prior art keywords
treatment
allergy
vaccination against
peptide
peptide immunogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002245497A
Other languages
French (fr)
Other versions
CA2245497C (en
Inventor
Franz Kricek
Beda Stadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26308839&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2245497(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9604412.8A external-priority patent/GB9604412D0/en
Priority claimed from GBGB9617702.7A external-priority patent/GB9617702D0/en
Application filed by Individual filed Critical Individual
Publication of CA2245497A1 publication Critical patent/CA2245497A1/en
Application granted granted Critical
Publication of CA2245497C publication Critical patent/CA2245497C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Immunogenic molecules comprising (a) at least one moiety of a peptide mimicking the natural epitope on human IgE recognized by the monoclonal anti-human IgE antibody BSW17, and (b) a moiety capable of eliciting an immune response against that peptide. They are useful in, or for the preparation of, pharmaceutical compositions, particularly for the treatment of IgE-mediated diseases such as allergies and atopic dermatitis, e.g. vaccines against allergy.
CA002245497A 1996-03-01 1997-02-28 Peptide immunogens for vaccination against and treatment of allergy Expired - Fee Related CA2245497C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9604412.8A GB9604412D0 (en) 1996-03-01 1996-03-01 Organic compounds
GB9604412.8 1996-03-01
GB9617702.7 1996-08-22
GBGB9617702.7A GB9617702D0 (en) 1996-08-22 1996-08-22 Organic compounds
PCT/EP1997/001013 WO1997031948A1 (en) 1996-03-01 1997-02-28 Peptide immunogens for vaccination against and treatment of allergy

Publications (2)

Publication Number Publication Date
CA2245497A1 true CA2245497A1 (en) 1997-09-04
CA2245497C CA2245497C (en) 2009-02-24

Family

ID=26308839

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002245497A Expired - Fee Related CA2245497C (en) 1996-03-01 1997-02-28 Peptide immunogens for vaccination against and treatment of allergy

Country Status (25)

Country Link
US (1) US6610297B1 (en)
EP (1) EP0885244B2 (en)
JP (2) JP3421970B2 (en)
KR (2) KR100498198B1 (en)
CN (1) CN1174998C (en)
AT (1) ATE230417T1 (en)
AU (1) AU719609B2 (en)
BR (1) BR9707819A (en)
CA (1) CA2245497C (en)
CY (1) CY2457B1 (en)
CZ (1) CZ299551B6 (en)
DE (1) DE69718150T3 (en)
DK (1) DK0885244T4 (en)
ES (1) ES2190799T5 (en)
HK (1) HK1014962A1 (en)
HU (1) HUP9901109A3 (en)
IL (1) IL125590A (en)
NO (1) NO321043B1 (en)
NZ (1) NZ331651A (en)
PL (1) PL187209B1 (en)
RU (1) RU2193413C2 (en)
SI (1) SI0885244T2 (en)
SK (1) SK284856B6 (en)
TR (1) TR199801722T2 (en)
WO (1) WO1997031948A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1621209A3 (en) * 1998-11-02 2006-04-19 Resistentia Pharmaceuticals AB Vaccines based on domains of chimeric immunoglobulin E peptides
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
ATE412434T1 (en) 1998-11-30 2008-11-15 Cytos Biotechnology Ag MOLECULAR ARRANGEMENT OF ALLERGENS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
JP2002537354A (en) * 1999-02-25 2002-11-05 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム Peptides, and H. Immunogen comprising a carrier derived from protein D of H. influenzae
MXPA01008612A (en) * 1999-02-25 2003-06-24 Smithkline Beecham Biolog Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
CA2405290C (en) * 2000-04-13 2011-06-21 Bio Life Science Forschungs Und Entwicklungsgesellschaft Mbh Vaccine against cancerous diseases
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US6887472B2 (en) 2000-08-30 2005-05-03 Pfizer Inc. Anti-IgE vaccines
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
EP1236740B1 (en) * 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vaccine against HER-2/neu oncogene-associated cancers
EP1239032A1 (en) 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP2003047482A (en) 2001-05-22 2003-02-18 Pfizer Prod Inc IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY
EP1497654A4 (en) 2001-08-13 2006-06-07 Chen Swey Shen Alex Immunoglobulin e vaccines and methods of use thereof
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
ATE361097T1 (en) * 2002-01-15 2007-05-15 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh ORAL VACCINATION WITH THE TUMOR ANTIGEN MIMOTOP GLN-MET-TRP-ALA-PRO-GLN-TRP-GLY-PRO-ASP
JP4726483B2 (en) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー Molecular antigen array
CA2487849A1 (en) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
DK1524994T3 (en) 2002-07-19 2011-08-15 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta 1-6 antigen arrays
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
US20050239757A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of macular degeneration
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
ITMI20052517A1 (en) * 2005-12-29 2007-06-30 Lofarma Spa VARIANBTIO HYPOALLERGENICS OF ALLERGENE GREATER BET V 1 BERRY OF BETULA VERRUCOSA
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc Fc riib-specific antibodies and methods of use thereof
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
EP2942061A3 (en) * 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
RU2761431C9 (en) * 2020-10-26 2022-04-18 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Recombinant polypeptide based on birch pollen allergen and apple allergen as an allergy vaccine

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2602443A1 (en) 1975-04-04 1976-10-21 Univ California BIOLOGICALLY ACTIVE POLYPEPTIDES
US4171299A (en) 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
EP0000252B1 (en) 1977-06-29 1982-02-03 Beecham Group Plc Peptides, pharmaceutical compositions containing the peptides and a process for the preparation of the peptides
JPS5944399A (en) 1982-09-07 1984-03-12 Takeda Chem Ind Ltd Novel dna
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
EP0269455A3 (en) 1986-11-28 1989-09-06 Takeda Chemical Industries, Ltd. Highly purified fused protein comprising human ige fc fragment and production thereof
WO1988006040A1 (en) 1987-02-20 1988-08-25 Imclone Systems, Inc. Monoclonal antibodies in vaccine formulations
CA1336818C (en) 1987-04-16 1995-08-29 International Institute Of Cellular And Molecular Pathology Treatment of allergy and composition thereof
ATE152244T1 (en) 1987-10-13 1997-05-15 Terrapin Tech Inc METHOD FOR PRODUCING IMMUNODIAGNOSIS AGENTS
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
US5342924A (en) 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
CA2074089C (en) 1990-01-23 2001-04-10 Tse-Wen Chang Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
ES2077857T3 (en) 1990-05-25 1995-12-01 Peptide Therapeutics Ltd IMMUNODIAGNOSTIC TEST FOR RHEUMATOID ARTHRITIS.
US5258289A (en) 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
JP3457962B2 (en) * 1991-08-14 2003-10-20 ジェネンテク，インコーポレイテッド Immunoglobulin variants for specific Fcε receptors
SE9102808L (en) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo VACCIN, HOW TO USE HUMAN USE, WILL BE INTENDED TO EFFECT THE SYMPTOMS OR PREVENT THE RISE OF IGE-MEDIATED ALLERGIC REACTIONS
GB9125024D0 (en) 1991-11-25 1992-01-22 Kirby Julian Rheumatoid arthritus treatment
JPH06113881A (en) 1992-10-07 1994-04-26 Snow Brand Milk Prod Co Ltd Human type monoclonal antipeptide antibody and dna capable of coding the same
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
JP3795914B2 (en) 1993-04-27 2006-07-12 ユナイテッド・バイオメディカル・インコーポレイテッド Immunogenic LHRH peptide constructs for vaccines and synthetic universal immune stimulators
AU6909194A (en) 1993-05-14 1994-12-12 Board Of Regents, The University Of Texas System Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
GB9320897D0 (en) 1993-10-11 1993-12-01 Peptide Therapeutics Ltd Compounds useful in anti-allergy treatment
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
FR2715304B1 (en) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Anti-allergic vaccine.
JPH09510975A (en) * 1994-03-28 1997-11-04 ユナイテッド・バイオメディカル・インコーポレイテッド Synthetic peptide-based immunogen for the treatment of allergies
WO1996001643A1 (en) 1994-07-08 1996-01-25 Thomas Jefferson University IgE ANTAGONISTS
WO1996012740A1 (en) 1994-10-25 1996-05-02 United Biomedical, Inc. SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY
WO1998024808A2 (en) 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
EP0955311A3 (en) 1998-04-09 2000-08-16 Idexx Laboratories, Inc. Peptide vaccine for canine allergy
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens

Also Published As

Publication number Publication date
PL328858A1 (en) 1999-03-01
NO983999D0 (en) 1998-08-31
DK0885244T3 (en) 2003-04-22
DE69718150T2 (en) 2003-08-21
SK284856B6 (en) 2006-01-05
AU1879697A (en) 1997-09-16
JP3421970B2 (en) 2003-06-30
KR100584051B1 (en) 2006-05-30
NO321043B1 (en) 2006-03-06
CN1174998C (en) 2004-11-10
DE69718150D1 (en) 2003-02-06
SI0885244T2 (en) 2008-10-31
DK0885244T4 (en) 2008-06-16
KR100498198B1 (en) 2005-09-09
RU2193413C2 (en) 2002-11-27
HK1014962A1 (en) 1999-10-08
CN1213380A (en) 1999-04-07
ES2190799T5 (en) 2008-08-16
US6610297B1 (en) 2003-08-26
JP2000502571A (en) 2000-03-07
ES2190799T3 (en) 2003-08-16
NZ331651A (en) 2000-01-28
NO983999L (en) 1998-11-02
IL125590A (en) 2001-08-26
HUP9901109A3 (en) 1999-11-29
WO1997031948A1 (en) 1997-09-04
AU719609B2 (en) 2000-05-11
IL125590A0 (en) 1999-03-12
CZ277198A3 (en) 1998-12-16
EP0885244B1 (en) 2003-01-02
CA2245497C (en) 2009-02-24
DE69718150T3 (en) 2009-03-05
CY2457B1 (en) 2005-06-03
BR9707819A (en) 1999-07-27
PL187209B1 (en) 2004-06-30
KR20050049509A (en) 2005-05-25
CZ299551B6 (en) 2008-08-27
JP2003231696A (en) 2003-08-19
SI0885244T1 (en) 2003-06-30
EP0885244B2 (en) 2008-04-16
TR199801722T2 (en) 1998-12-21
SK118198A3 (en) 1999-03-12
EP0885244A1 (en) 1998-12-23
KR19990087425A (en) 1999-12-27
HUP9901109A2 (en) 1999-07-28
ATE230417T1 (en) 2003-01-15

Similar Documents

Publication Publication Date Title
CA2245497A1 (en) Peptide immunogens for vaccination against and treatment of allergy
CA2217178A1 (en) Vaccines containing a saponin and a sterol
CA2001328A1 (en) Borrelia antigen
EP2325205A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
RU95105991A (en) Conjugate, vaccine, methods of immunogenicity enhancement, methods of immunization
WO1999044636A3 (en) Il-12 enhancement of immune responses to t-independent antigens
CA2204253A1 (en) Methods and devices for immunizing a host through administration of naked polynucleotides which encode antigenic peptides
NZ319377A (en) polypeptides comprising a portion of a soluble M tuberculosis antigen
NO913518L (en) VACCINES FOR NON-TYPE-TESTABLE HAEMOPHILUS INFLUENZAE.
EP1731166A3 (en) Streptococcus pneumoniae proteins and vaccines
NO912825D0 (en) PROCEDURE FOR THE PREPARATION OF COCONJUGATE VACCINES INCLUDING IMMUNOGENIC PROTEIN, HIV RELATED PEPTIDES AND ANIONIC GROUPS.
WO2003065973A8 (en) Multivalent streptococcal vaccine compositions and methods for use
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
WO2001072277A3 (en) Immunotherapeutic methods and compositions
WO2005007673A3 (en) Immunogenic peptides
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO1997047271A3 (en) Cellular vaccines and immunotherapeutics and methods for their preparation
EP1801123A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
CA2273922A1 (en) Novel saponin compositions and uses thereof
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
WO2002036160A3 (en) Method for obtaining antigenic structures enhancing specific cross reactivity
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor
WO1999015692A3 (en) Dengue virus antigens and treatment of dengue fever

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed